Publikasi Scopus Covid-19 Per 15 Juni 2023 (346 artikel)

Lazarus, Gilbert (57214599425); Budiman, Refael Alfa (57224981676); Rinaldi, Ikhwan (23475122400)
Lazarus G.; Budiman R.A.; Rinaldi I.
Does immune checkpoint inhibitor increase the risks of poor outcomes in COVID-19-infected cancer patients? A systematic review and meta-analysis
Cancer Immunology, Immunotherapy
Background: The association between immune checkpoint inhibitor (ICI) and outcomes of cancer patients with coronavirus disease 2019 (COVID-19) infection has yet to be systematically evaluated. This meta-analysis aims to investigate the effects of ICI trea
Checkpoint inhibitor; COVID-19; Neoplasms; Prognosis; Programmed cell death 1 receptor
The authors would like to express their gratitude to Dr. Ying Taur and Dr. Mini Kamboj (Infectious Diseases, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA) for the provision of additional data for analyses. The authors
G. Lazarus; Faculty of Medicine, Universitas Indonesia, Kota Jakarta Pusat, Jl. Salemba Raya No. 6, RW 5, Kenari, Kec. Senen, Jakarta, 10430, Indonesia; email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Springer Science and Business Media Deutschland GmbH
03407004
34173850
Cancer Immunol. Immunother.
Lazarus G., Faculty of Medicine, Universitas Indonesia, Jl. Salemba Raya No. 6, RW 5, Kenari, Kec. Senen, Jakarta, Kota Jakarta Pusat, 10430, Indonesia; Budiman R.A., Faculty of Medicine, Universitas Indonesia, Jl. Salemba Raya No. 6, RW 5, Kenari, Kec. S
Faculty of Medicine, Universitas Indonesia, Jl. Salemba Raya No. 6, RW 5, Kenari, Kec. Senen, Jakarta, Kota Jakarta Pusat, 10430, Indonesia; Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Universitas Ind
57214599425; 57224981676; 23475122400
6
2022
Article